ERBB2 and breast cancer: In the phase III EMILIA trial T-DM1 was compared to lapatinib plus capecitabine, the most used treatment at that time in 2nd line, in 991 patients with HER2-positive BC previously treated with trastuzumab and taxanes [8, 16].